Aizhan Kubeyeva

Aizhan Kubeyeva

Auto-generated profile, based on publicly available information

Aizhan Kubeyeva

Department of Cardiology, S.D. Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2021 in Journal of Clinical Medicine of Kazakhstan
Verified
Journal Article
Open access
PDF file
KKKamilya Kedelbayeva
Kamilya Kedelbayeva
SBSalim Berkinbaev
Salim Berkinbaev
GDGulnar Dzhunusbekova
Gulnar Dzhunusbekova
MTMeyramgul Tundybaeva
Meyramgul Tundybaeva
AKAizhan Kubeyeva
Aizhan Kubeyeva
DUDarya Utebaliyeva
Darya Utebaliyeva
Cardiovascular disease is a major contributor to morbidity, mortality and quality of life in people aged 60 and over. However, this age group of patients was not sufficiently included in large studies, in this regard, the management of elderly patients is an urgent problem in modern medicine. The purpose of this review is to analyze of literature data on the characteristics comorbid pathology and senile asthenia as a predictor of unfavorable course and outcomes of acute myocardial infarction in patients 60 years of age and older. To analyze the literature, we searched for information on this issue in PubMed / MEDLINE, PMC, Web of Science, Scopus, The Сocrane Library. Recent research data show that there are plenty of risk factors for worsening the course of AMI in patients aged 60 and over. The most important of them are considered to be high comorbidity, multivessel lesion of several pools, the presence of senile asthenia. All together lead to difficulties in diagnosing myocardial infarction, to forced polypharmacy and in some cases refraining from early invasive strategy, which worsens the course of the disease, increases the duration of hospital treatment, leads to frequent complications, thereby affects the prognosis of the disease and leads to the development of early disability in patients 60 years of age and older In the vast majority of elderly patients, the development of acute myocardial infarction occurs against the background of a high prevalence of comorbid pathology, which in turn accelerates the development of senile asthenia and its progression.

31 August 2021 in Наука и здравоохранение
Verified
Journal Article
Open access
KKKamilya Kedelbayeva
Kamilya Kedelbayeva
BSBerkinbaev S.F.
Berkinbaev S.F.
DGDzhunusbekova G.A.
Dzhunusbekova G.A.
TMTundybaeva M.K.
Tundybaeva M.K.
KAKubeyeva A.SH.
Kubeyeva A.SH.
Introduction: The presence of high comorbidity, risk factors lead to a worsening of the course and an unfavorable outcome of acute myocardial infarction (AMI). Taking into account gender and age characteristics, the study of the most important risk factors will help in the future create activities focused on combating comorbidity. The main benefit of this work is the identification and management of high-risk patients. The aim of the study: study of risk factors, structure and severity of comorbid pathology and its influence on the clinical course of AMI in different gender-age groups of patients. Materials and methods: The retrospective study included case histories of 634 patients with a favorable outcome of AMI. The study group is represented by 63.9% of men and 36.1% of women. The comorbidity of AMI patients was assessed using the Charlson comorbidity index (IC). The patients were divided into 3 groups: Group I (low comorbidity, ICR≤3 points); Group II (average comorbidity, CI 3-5 points); Group III (high comorbidity, CI ≥5 points). Results and discussion: Compared to women, men were more likely to have AH 89.7%, hypercholesterolemia 75%, overweight 40%, smoking 31.5%, obesity 31%, diabetes mellitus 24.4% and impaired glucose tolerance in 20% of patients. The average number of nosologies was 3.7 ± 1.04. The Charlson comorbidity index is 5.5 ± 1.9 points. There was a high 47.3% and moderate comorbidity of 48.3%. A high comorbidity index was found in men (49.7%), in women (50.3%). Patients with high comorbidity often had recurrent AMI (59.1%, p = 0.001). A direct correlation was found between the severity of coronary artery disease, age, and the severity index of comorbidity (r = 0.32, p = 0.001). Compared to the three women, the vascular lesion of the coronary bed was more detected in men 64.1%, p = 0.001. Considering the structure and severity of comorbid pathology in patients with AMI, there was a low 10-year survival rate according to the comorbidity index. Conclusion: Most of the patients with risk factors and comorbid pathology were men. The patients with AMI studied by us had high and moderate comorbidity; more often these patients had repeated AMI, multivessel coronary artery disease and a decrease in the frequency of coronary angiography, then PCI. When calculating the comorbidity index, a low 10-year survival rate was revealed. This work proves the need for timely correction of risk factors, improvement of comorbidity management tactics, which helps to reduce the unfavorable course of AMI. Введение: Наличие высокой коморбидности факторов риска ведут к ухудшению течения и неблагоприятному исходу острого инфаркта миокарда (ОИМ). Учитывая гендерные и возрастные особенности, изучение наиболее важных факторов риска помогут в дальнейшем создавать мероприятия, ориентированные на борьбу с коморбидностью. Основным благоприятным результатом в этой работе является выявления пациентов повышенного риска и работа с ними. Цели исследования: изучение факторов риска, структуры и степени тяжести коморбидной патологии и ее влияние на клиническое течение ОИМ у различных гендерно-возрастных групп пациентов. Материалы и методы: В ретроспективное исследование были включены истории болезни 634 пациентов с благоприятным исходом ОИМ. Исследуемая группа представлена: 63,9% мужчин и 36,1% женщин. Коморбидность больных ОИМ оценивали с помощью индекса коморбидности (ИК) Чарлсона. Больные были разделены на 3 группы: I группа (низкая коморбидность, ИКЧ≤3 балла); II группа (средняя коморбидность, ИКЧ 3-5 баллов); III группа (высокая коморбидность, ИКЧ ≥5 балла). Результаты: По сравнению с женщинами у мужчин чаще встречались АГ - 89,7%, гиперхолестеринемия - 75%, избыточная масса тела - 40%, курение - 31,5%, ожирение - 31%, СД - 24,4% и нарушение толерантности к глюкозе у 20% пациентов. Среднее количество нозологий составило 3,7±1,04. Индекс коморбидности Чарлсона 5,5±1,9 балла. Отмечалась высокая у 47,3% и средней степени тяжести коморбидность у 48,3%. Высокий индекс коморбидности встречался у мужчин (49,7%), у женщин (50,3%). У больных с высокой коморбидностью часто встречались повторный ОИМ (59,1%, р=0,001). Выявлена прямая корреляционная связь между степенью тяжести поражения коронарных артерий, возрастом и индексом тяжести коморбидности (r=0,32, p=0,001). По сравнению с женщинами трех сосудистое поражение коронарного русла больше выявлялось у мужчин 64,1%, р=0,001. Учитывая структуру и степень тяжести коморбидной...

30 April 2020 in International Professional Journal "Medicine"
Verified
Journal Article
Closed access
GJGulnara Junusbekova
Gulnara Junusbekova
MTMeiramgul Tundybayeva
Meiramgul Tundybayeva
TLTatyana Leonovich
Tatyana Leonovich
MYManshuk Yeshniyazova
Manshuk Yeshniyazova
RNRizvangul Namatova
Rizvangul Namatova
ACAlmaty City Cardiological Center
Almaty City Cardiological Center
Arterial hypertension (AH) remains one of the most common diseases in the world. Reducing cardiovascular risk of mortality from cardiovascular complications is a priority in the treatment of hypertension. Targets of hypertension therapy is to achieve SBP/DBP <140/80 mm Hg. article, regardless of cardiovascular risk and comorbidity. The choice of antihypertensive therapy depends on blood pressure levels, the presence or absence of concomitant diseases, lesion of target organs. Effective and long-lasting control of AH proved by the use of combinations of antihypertensive drugs, including antagonists and ACE inhibitors. The purpose of the study. Evaluation of clinical efficacy and safety of fixed combination antihypertensive therapy using lisinopril combined with amlodipine in patients with hypertension. Material and methods. The study included 30 respondents from essential hypertension II-III degree (ESH/ESC, 2018) aged 35 to 75 years. Patients were treated with the schema a (lisinopril 10 mg, amlodipine 5 mg) and scheme b (lisinopril 20 mg, amlodipine 10 mg) fixed combination therapy with the drug VivaCor® once in the morning. The period of observation was 3 months. At the time of inclusion and at the end of the study all respondents was performed echocardiography, daily monitoring of blood pressure, evaluation of laboratory and instrumental methods of research. Results and discussion. The combination of lisinopril with amlodipine has a fairly high antihypertensive activity, provides a significant cardioprotective effect and is an integral part of antihypertensive therapy in the long-term strategy of administering patients with high hypertensive / very high total cardiovascular risk. Conclusions: 1. The use of a fixed combination of lisinopril and amlodipine in patients with hypertension instead of free or other two-component combinations leads to its target level within 3 months of therapy. 2. Taking a fixed combination of lisinopril and amlodipine is effective and safe. 3. Therapy using the combined drug VivaCor® in patients with high / very high risk of hypertension prevents further pathological remodeling of the heart. 4. The combination of amlodipine and lisinopril is metabolically neutral and well tolerated by patients. Keywords: arterial hypertension, lisinopril, amlodipine, VivaCor.